Period of time： 2005年1期
Publisher： Informa Healthcare
Founded in： 2001
Total resources： 8
ISSN： 1473-3404
Subject： R73 Oncology
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
The Women's Oncology Review,volume 4,issue 1
Menu
The 'best' of the breast papers (2002) and how they affect everyday practice
The Women's Oncology Review,volume 4,issue 1 , Vol. 4, Iss. 1, 2004-01 , pp.
Access to resources
Recommend
Uterine sarcomas: a 10-year experience and a review of the literature
By Yildirim Yusuf,İnal M. Murat,Sanci Muzaffer,Şentaş Abdulmuttalip,Hanhan Merih in (2004)
The Women's Oncology Review,volume 4,issue 1 , Vol. 4, Iss. 1, 2004-01 , pp.MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer
By Julien-Grille Sylvia,Bellacosa Alfonso,Larue Lionel in (2004)
The Women's Oncology Review,volume 4,issue 1 , Vol. 4, Iss. 1, 2004-01 , pp.By Sanseverino Francesca,Torricelli Michela in (2004)
The Women's Oncology Review,volume 4,issue 1 , Vol. 4, Iss. 1, 2004-01 , pp.By Torricelli Michela,Sanseverino Francesca in (2004)
The Women's Oncology Review,volume 4,issue 1 , Vol. 4, Iss. 1, 2004-01 , pp.VEGF and HIF-1α expression are increased in advanced stages of epithelial ovarian cancer
By Lovergine Silvia,Masciullo Valeria in (2004)
The Women's Oncology Review,volume 4,issue 1 , Vol. 4, Iss. 1, 2004-01 , pp.Circulating levels of insulin-like growth factor II and IGF-binding protein 3 in cervical cancer
By Lovergine Silvia,Masciullo Valeria in (2004)
The Women's Oncology Review,volume 4,issue 1 , Vol. 4, Iss. 1, 2004-01 , pp.A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
The Women's Oncology Review,volume 4,issue 1 , Vol. 4, Iss. 1, 2004-01 , pp.
Previous
Next